10-Q: Isotopes Inc. Narrows Loss, Boosts Revenue in Q2 2025

International Isotopes Inc. reported a reduced net loss and increased revenue for the second quarter and first half of 2025, driven by strong Nuclear Medicine Standards sales.

Summary

• Net loss for the six months ended June 30, 2025, decreased to $273,479 from $387,496 in the same period of 2024, an improvement of 29.4%.
• Total product sales for the six months ended June 30, 2025, increased by 14% to $6,894,220, up from $6,073,691 in the prior year period.
• Gross profit for the six months ended June 30, 2025, rose by 7% to $4,173,596, compared to $3,883,622 in the same period of 2024.
• Net cash provided by operating activities increased to $310,446 for the six months ended June 30, 2025, from $288,597 in the prior year period.
• Nuclear Medicine Standards segment sales surged by 99% to $2,340,580 for the six months ended June 30, 2025, primarily due to the absence of a Cobalt-57 isotope shortage experienced in 2024.
• Theranostics Products sales decreased by 9% to $3,692,456 for the six months ended June 30, 2025, attributed to a two-week temporary supplier outage.
• Cobalt Products sales decreased by 9% to $750,465 for the six months ended June 30, 2025, and the segment reported a net loss of $245,266 due to $129,000 in waste expenses.
• Medical Device Products segment generated $110,719 in sales for the six months ended June 30, 2025, but incurred a net loss of $382,974 due to increased development activity.
• Cash and cash equivalents stood at $1,859,424 as of June 30, 2025, a decrease of 4% from $1,945,523 at December 31, 2024.
• Promissory notes with related parties (2013, 2018, 2019 Promissory Notes) had their maturity dates extended to March 31, 2028, in August 2025.
• The sale of the Fluorine Products segment and Planned Uranium De-Conversion Facility, with potential proceeds of $12.5 million, remains contingent on buyer financing and approvals, with an Outside Date of March 31, 2026.

Sentiment

Score: 5

Explanation: The company shows positive revenue growth and a reduced net loss, indicating some operational improvements. However, it continues to incur losses, faces supply chain vulnerabilities, and relies on related-party debt extensions. The delay in new product launches and uncertainty around the Fluorine Products sale temper the positive financial trends.

Positives

• Net loss significantly reduced by 29.4% for the six months ended June 30, 2025, compared to the prior year.
• Total product sales increased by 14% for the six months ended June 30, 2025, demonstrating overall revenue growth.
• Net cash provided by operating activities increased to $310,446, indicating improved operational cash generation.
• Nuclear Medicine Standards segment experienced a substantial 99% sales increase, recovering from prior year supply shortages.
• Secured regulatory approval for an additional supplier for Theranostics Products, enhancing supply chain resilience.
• Promissory notes with related parties were extended to March 31, 2028, providing additional liquidity runway.

Negatives

• Continued to incur a net loss of $273,479 for the six months ended June 30, 2025.
• Gross profit percentage decreased to 61% for the six months ended June 30, 2025, from 64% in the prior year.
• Theranostics Products sales decreased by 9% due to a temporary two-week supplier outage.
• Cobalt Products segment reported a net loss of $245,266, primarily due to $129,000 in waste expenses.
• Medical Device Products segment, while generating sales, incurred a significant net loss of $382,974 due to development costs.
• Cash and cash equivalents decreased by 4% from December 31, 2024.
• The release of RadVent products (Swirler and Tru-Fit Mouthpiece) from the Medical Device segment is delayed to early 2026 due to tariff issues.

Risks

• Incurred substantial losses since inception, raising concerns about long-term profitability.
• Dependence on a small number of customers, with the top three customers accounting for approximately 32% of total gross revenue and one customer in Theranostics Products accounting for 18%.
• Reliance on the U.S. Department of Energy (DOE) for Cobalt-60 production, with potential for supply interruptions.
• Dependence on a few key suppliers for Theranostics Products, despite adding an additional supplier.
• Global outage of Gadolinium-153 isotopes has resulted in significant lost sales for the Nuclear Medicine Standards segment, with an uncertain timeframe for supply restoration.
• No assurance that additional capital and financing will be available on acceptable terms or at all to fund future operations.
• The sale of the Fluorine Products segment and Planned Uranium De-Conversion Facility is contingent on the buyer obtaining financing and regulatory approvals, creating uncertainty regarding the $12.5 million in potential proceeds.

Future Outlook

Management expects continued sales growth for Theranostics Products, driven by generic sodium iodide I-131 drug product and new theranostic API products. The Medical Device segment's Swirler and Tru-Fit Mouthpiece products, under the RadVent brand, are now expected to be released in early 2026, a delay from late 2025 due to tariff issues. The EasyFill Automated Iodine Capsule System remains in the developmental stage. The company anticipates that cash from operations, equity or debt financing, and current cash balances will be sufficient to fund operations for the next twelve months, though there is no assurance that additional capital will be available on acceptable terms.

Management Comments

• Expect cash from operations, equity or debt financing, and current cash balance to be sufficient to fund operations for the next twelve months.
• Future liquidity and capital funding requirements will depend on numerous factors, including commercial relationships, technological developments, market factors, available credit, and management of redeemable convertible preferred stock.
• There is no assurance that additional capital and financing will be available on acceptable terms to the Company or at all.

Industry Context

The company operates in the nuclear medicine and isotope industry, which is characterized by high regulatory barriers (NRC licensing), dependence on specialized suppliers (DOE for Cobalt-60, specific radioisotope suppliers), and evolving medical device technology. The global shortage of Cobalt-57 in 2024 and Gadolinium-153 in 2025 highlights the supply chain vulnerabilities inherent in this specialized market. The company's strategic alliances, such as the joint venture with Alpha Nuclide for the China market and PhanQual with Phantech, reflect efforts to expand market reach and diversify product offerings in a niche but critical healthcare sector. The delay in medical device product launches due to tariff issues indicates broader global trade challenges impacting specialized manufacturing.

Comparison to Industry Standards

• The company's gross profit percentage of 61% for the six months ended June 30, 2025, while strong, decreased from 64% in the prior year. This compares to other specialized pharmaceutical or medical device companies where gross margins can vary widely but often exceed 50% due to intellectual property and regulatory barriers.
• The continued net loss, despite revenue growth, indicates ongoing challenges in achieving profitability, which is common for development-stage or niche-market companies in highly regulated industries, but contrasts with more mature, profitable industry players.
• The dependence on a few key customers (32% from top three, 18% from one Theranostics customer) is higher than industry best practices for diversification, which typically aim for no single customer exceeding 10-15% of revenue to mitigate concentration risk.
• The repeated extensions of related party promissory notes (2013, 2018, 2019 notes extended to March 31, 2028) suggest a reliance on insider financing that is not typical for financially robust, publicly traded companies, which usually access broader capital markets for long-term debt.
• The company's NRC construction and operating license for the depleted uranium de-conversion facility is noted as the first commercial license of its type in the U.S., positioning it uniquely in the domestic nuclear fuel cycle industry, though the sale of this segment introduces uncertainty.

Legal Proceedings

• The company is required to have an operating license from the NRC for handling radioactive material, with financial assurance provided by a surety bond supported by a restricted money market account of $1,462,280.

Related Party Transactions

• The 2013 Promissory Note ($500,000) is with a then Chairman of the Board and a major shareholder.
• The 2018 Promissory Note ($120,000) is with the Chief Executive Officer and Chairman of the Board.
• The 2019 Promissory Note ($1,000,000 aggregate) is with the Chief Executive Officer, Chairman of the Board, former Chairman of the Board, and major shareholders.
• The promissory note with AMICI ($187,100 balance) is related to an asset purchase agreement.

Stakeholder Impact

• Shareholders: Experience dilution from shares issued under employee stock purchase plans, stock in lieu of dividends on preferred stock, and potential future equity financing. Net losses continue to impact accumulated deficit.
• Employees: Benefit from employee stock purchase plans and stock-based compensation. Increased headcount and payrates indicate growth in employment.
• Customers: May experience product availability issues due to supplier outages (e.g., Theranostics, Gadolinium-153) but also benefit from new product introductions (Medical Devices) and expanded distribution (China JV).
• Suppliers: The company's dependence on a few key suppliers for critical isotopes and materials creates risk for both the company and its suppliers if relationships are disrupted.
• Creditors: Related party creditors have repeatedly extended maturity dates on promissory notes, indicating ongoing financial accommodation and reliance on these relationships.

Next Steps

• Continue focus on Theranostics Products, Cobalt Products, and Nuclear Medicine Standards segments, pursuing new business opportunities.
• Focus on the start-up of the Medical Device segment, including assets purchased from AMICI and investing in the EasyFill Automated Iodine Capsule System.
• Commercialize additional third-party medical devices and accessories related to radiopharmaceutical and theranostics spaces.
• Release Swirler and Tru-Fit Mouthpiece products under the RadVent brand in early 2026.
• Further milestones for the Strategic Development and Distribution Agreement with Alpha Nuclide Inc include establishing a joint venture to register Theranostics & Nuclear Medicine Products with the CFDA for local manufacturing and distribution in China.
• Work with industry to restart supply of Gadolinium-153 isotopes.
• Evaluate the impact of ASU 2023-09 (Income Taxes) for its annual reporting for fiscal 2025.

Key Dates

Recommendation

While the company demonstrated positive revenue growth and a reduced net loss, it remains unprofitable and faces significant operational risks, including customer and supplier concentration, and ongoing reliance on related-party debt. The potential $12.5 million sale of the Fluorine Products segment is a key future catalyst, but its closing is uncertain. The delay in new medical device product launches due to external factors adds to the uncertainty. Given the mixed financial performance, the inherent risks in its specialized industry, and the reliance on future financing, a 'hold' recommendation is appropriate for a seasoned investor, pending clearer signs of sustained profitability and successful execution of strategic initiatives.

Keywords

Nuclear Medicine, Isotopes, Radiopharmaceuticals, Cobalt-60, Medical Devices, SEC Filing, 10-Q, Financial Results, Theranostics, De-Conversion Facility